Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...
Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...
In a significant move aimed at strengthening regulatory clarity for cancer related medical technologies, the Central Drugs ...
News-Medical.Net on MSN
Common blood signals explain why chronic diseases cluster as we age
This population-based study shows that shared and pattern-specific blood biomarkers reflect biological vulnerability ...
Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical ...
GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback